Cleveland Clinic | Strategic Alliance Partners

February 25, 2022

Nima Sharifi, MD, PLCO, discusses the results of the prostate cancer cohort in the PLCO trial and how PAGln could be linked to patients eventually diagnosed with lethal prostate cancer.

February 25, 2022

Light-chain amyloidosis is a rare plasma cell disorder that involves the production of a misfolded amyloidogenic light chain by a plasma cell clone that deposits in various organs leading to organ failure.

February 16, 2022

Aaron T. Gerds, MD, MS, discusses the use of TKIs, targeted agents, JAK inhibitors, and cellular therapy in hematologic malignancies.

February 14, 2022

Nima Sharifi, MD, director, discusses the methodologies utilized when evaluating the correlation between gut microbiome and fatal prostate cancer.

February 10, 2022

Nima Sharifi, MD, discusses the rationale to evaluate the correlation between the gut microbiome and the aggressiveness of prostate cancer.

February 10, 2022

We had the pleasure of speaking with faculty from an OncLive® Institutional Perspectives in Cancer webinar on hematologic malignancies, hosted in partnership with Cleveland Clinic, to discuss current practice patterns and emerging therapies in chronic myeloid leukemia, chronic lymphocytic leukemia, myelofibrosis, and acute lymphoblastic leukemia.

February 09, 2022

Brian T. Hill, MD, PhD, discusses the potential utility of next-generation PI3K inhibitors in chronic lymphocytic leukemia.

January 27, 2022

Aaron T. Gerds, MD, MS, discusses emerging agents in myelofibrosis.

January 17, 2022

Aaron T. Gerds, MD, MS, discusses the rationale for the real-world REVEAL study in polycythemia vera.

December 14, 2021

Patients with polycythemia vera who have controlled hematocrit levels, but elevated white blood counts are at an increased risk of thrombotic events, according to a presentation of the REVEAL study.

December 06, 2021

Andrea Moreira, MD, a board-certified plastic surgeon specializing in the use of advanced techniques in breast reconstruction, has joined Allegheny Health Network from Cleveland Clinic and will serve as Co-Director of the Microsurgery and Breast Reconstruction Program in the AHN Division of Plastic Surgery.

December 02, 2021

Cleveland Clinic has partnered with Anixa Biosciences, Inc. to open a phase 1 trial examining a vaccine aimed at preventing the development of triple-negative breast cancer.

November 03, 2021

Radiation oncologists Jacob Scott, MD, DPhil, and Javier Torres-Roca, MD, discuss the benefits of using GARD in a pooled pan-cancer analysis and why there is a call to action to integrate GARD-based radiotherapy dosing in oncology.

November 02, 2021

Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.

September 30, 2021

Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices.

September 30, 2021

Cleveland Clinic has established a center focused on the diagnosis, care, and research of young-onset colorectal cancer.

September 24, 2021

The availability of targeted agents for patients with advanced non–small cell lung cancer who harbor mutations in EGFR, RET, MET, and KRAS has not only led to improved outcomes, but provided greater flexibility for treatment-naïve and pretreated populations, with the possibility of enhanced intracranial activity.

September 13, 2021

Pradnya D. Patil, MD, FACP, discusses the development of KRAS G12C inhibitors in lung cancer.

September 03, 2021

Genomic-adjusted radiation dose demonstrated a significant association with time to first recurrence and overall survival in patients with certain solid tumors who had been treated with radiation therapy, indicating that genomics should be used to guide radiation dosing decisions.

September 02, 2021

Pradnya D. Patil, MD, FACP, discusses data from the phase 3 ADAURA trial in patients with EGFR-mutated non–small cell lung cancer.